https://pharmatrophix.com/news/ 2026-05-12T16:19:11+00:00 https://pharmatrophix.com/positive-phase-2-interim-data-for-lm11a-31-in-alzheimers-disease/ 2026-05-05T05:35:44+00:00 https://pharmatrophix.com/wp-content/uploads/2026/04/about-image.jpg https://pharmatrophix.com/phase-2-interim-data-for-lm11a-31-in-alzheimers/ 2026-05-05T05:36:18+00:00 https://pharmatrophix.com/wp-content/uploads/2026/05/Three-people-discussing@2x.jpg https://pharmatrophix.com/series-c-closes-at-85m-to-expand-phase-2-enrollment/ 2026-05-05T05:37:56+00:00 https://pharmatrophix.com/wp-content/uploads/2026/05/Older-woman-puzzle@2x.jpg https://pharmatrophix.com/parkinsons-preclinical-program-advances-to-ind-enabling-studies/ 2026-05-10T05:05:19+00:00 https://pharmatrophix.com/wp-content/uploads/2016/02/alzheimers-cover-scaled.jpg https://pharmatrophix.com/dr-sarah-chen-joins-as-chief-medical-officer/ 2026-05-11T18:12:16+00:00 https://pharmatrophix.com/wp-content/uploads/2025/04/Screenshot-2026-05-05-at-1.36.29-AM.png https://pharmatrophix.com/p75-neurotrophin-receptor-modulation-in-mild-to-moderate-alzheimer-disease/ 2026-05-12T02:19:35+00:00 https://pharmatrophix.com/wp-content/uploads/2026/05/Older-younger-people@2x-2.jpg https://pharmatrophix.com/pharmatrophix-at-j-p-morgan-healthcare-conference/ 2026-05-12T02:39:43+00:00 https://pharmatrophix.com/wp-content/uploads/2026/05/Elderly-woman-tending-plant@2x.jpg https://pharmatrophix.com/targeting-upstream-neurodegeneration-lm11a-31-in-alzheimer-disease-and-psp/ 2026-05-12T16:19:11+00:00 https://pharmatrophix.com/wp-content/uploads/2026/05/1778538987676.png